Piper Sandler lowered the firm’s price target on Gilead to $95 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported Q4 numbers and total revenues of $7.1B along with non-GAAP EPS of $1.72, both generally in-line with PSC/consensus expectations.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GILD:
- Options Volatility and Implied Earnings Moves Today, February 06, 2024
- GILD Earnings this Week: How Will it Perform?
- Gilead Sciences Elects New Board Member and Audit Committee Participant
- Biotech Alert: Searches spiking for these stocks today
- FDA approves manufacturing process change for Kite’s Yescarta for TAT reduction
